Literature DB >> 36246824

Myeloid sarcoma with ulnar nerve entrapment: A case report.

Da-Peng Li1, Chao-Zong Liu2, Mortimer Jeremy2, Xin Li3, Jin-Chao Wang1, Swastina Nath Varma2, Ting-Ting Gai1, Wei-Qi Tian1, Qi Zou4, Yan-Mian Wei1, Hao-Yu Wang2, Chang-Jiang Long5, Yu Zhou6.   

Abstract

BACKGROUND: Myeloid sarcoma (MS) is relatively rare, occurring mainly in the skin and lymph nodes, and MS invasion of the ulnar nerve is particularly unusual. The main aim of this article is to present a case of MS invading the brachial plexus, causing ulnar nerve entrapment syndrome, and to further clinical understanding of the possibility of MS invasion of peripheral nerves. CASE
SUMMARY: We present the case of a 46-year-old man with a 13-year history of well-treated acute nonlymphocytic leukaemia who was admitted to the hospital after presenting with numbness and pain in his left little finger. The initial diagnosis was considered a simple case of nerve entrapment disease, with magnetic resonance imaging showing slightly abnormal left brachial plexus nerve alignment with local thickening, entrapment, and high signal on compression lipid images. Due to the severity of the ulnar nerve compression, we surgically investigated and cleared the entrapment and nerve tissue hyperplasia; however, subsequent pathological biopsy results revealed evidence of MS. The patient had significant relief from his neurological symptoms, with no postoperative complications, and was referred to the haemato-oncology department for further consultation about the primary disease. This is the first report of safe treatment of ulnar nerve entrapment from MS. It is intended to inform hand surgeons that nerve entrapment may be associated with extramedullary MS, as a rare presenting feature of the disease.
CONCLUSION: MS invasion of the brachial plexus and surrounding tissues of the upper arm, resulting in ulnar nerve entrapment and degeneration with significant neurological pain and numbness in the little finger, is uncommon. Surgical treatment significantly relieved the patient's nerve entrapment symptoms and prevented further neurological impairment. This case is reported to highlight the rare presenting features of MS. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Acute nonlymphocytic leukaemia; Case report; Myeloid sarcoma; Sarcoma; Ulnar nerve entrapment syndrome; Upper limb surgery

Year:  2022        PMID: 36246824      PMCID: PMC9561602          DOI: 10.12998/wjcc.v10.i28.10227

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.534


Core Tip: The main aim of this article is to present a rare case of myeloid sarcoma (MS) invading the ulnar nerve and causing ulnar nerve entrapment syndrome. The patient’s symptoms were relieved by surgical release of the nerve bundle and compressed tissue, and the disease was diagnosed definitively by pathological examination. The case illustrates the rare presenting features of extramedullary MS, enriches the clinical literature, and highlights that it is essential to suspect MS with a history of acute nonlymphocytic leukaemia.

INTRODUCTION

Myeloid sarcoma (MS), also known as granulocytic sarcoma and chloroma, is a rare haematological tumour consisting of a solid extramedullary mass of immature cells of the myeloid lineage, capable of destroying preexisting tissues and organs. It is more common in males than in females and is often associated with acute nonlymphocytic leukaemia (ANLL), which is frequently the primary manifestation of disease relapse[1-3]. MS develops mainly in the skin and lymph nodes but may affect almost any tissue or organ[4,5], and usually presents as an isolated mass of extramedullary infiltrates of leukaemia. To date, it is rare to encounter MS affecting the brachial plexus and producing ulnar nerve compression symptoms in the literature[6,7]. The main aim of this article is to present a case of ulnar nerve entrapment syndrome caused by MS invasion of the brachial plexus, furthering the clinical understanding of the potential for MS to involve peripheral nerves.

CASE PRESENTATION

Chief complaints

The patient was a 46-year-old man who complained of painful numbness in the left little finger for 4 mo with no apparent cause.

History of present illness

The numbness and pain in his left little finger had gradually worsened over the past 4 mo but was not of serious concern.

History of past illness

The patient had a 13-year history of ANLL and a 20-year history of psoriasis; both diseases had been fully treated previously by systemic therapy.

Personal and family history

Notably, there was no family history of the same disease.

Physical examination

Physical examination of the whole body revealed no palpable lymph nodes. Specialized examination of the left hand revealed atrophy of the first dorsal interosseous muscle, numbness of the little finger and ulnar aspect of the palm, weakness of the ring and little finger, inability to adduct fingers, positive paper-clip test results, and loss of manual dexterity; all other examination outcomes were normal.

Laboratory examinations

The laboratory results were: White blood cell count (WBC), 14.14 (normal range: 3.50-9.50) × 109/L; neutrophil count (NEUT), 12.12 (1.80-6.30) × 109/L; lymphocyte count (LYMPH), 0.78 (1.20-3.20) × 109/L; monocyte count, 1.22 (0.10-0.60) × 109/L; eosinophil count (EOS), 0.00 (0.02-0.52) × 109/L; %NEUT, 85.8 (40.0-75.0)%; %LYMPH, 5.50 (20-50)%; %EOS, 0.0 (0.4-8.0)%; red blood cell count (RBC), 4.0 (4.3-5.8) × 109/L; haemoglobin count (HGB), 126 (130-175) g/L; haematocrit, 36.2 (40.0-50.0)%; rheumatoid factors, 22.05 (≤ 18.00) IU/mL; hypersensitive C-reactive protein, 4.67 (≤ 4.00) mg/L; uric acid, 463.02 (202.00-416.00) μmol/L; and interferon-γ, 34.21 (≤ 20.36) pg/mL.

Imaging examinations

X-rays showed that the bones of the left elbow were regular in shape, with cortical continuity and clear trabecular structures, a normal alignment of the elbow joint with a moderate joint space, and no significant abnormalities in the surrounding soft tissues (Figure 1A and B). Magnetic resonance imaging (MRI) showed a slightly abnormal left brachial plexus nerve alignment with local thickening, entanglement, and a high signal on compression lipid imaging, while the right brachial plexus nerve bundle alignment was normal with no obvious abnormal signal. There were multiple somewhat large lymph nodes in the neck, with the largest being approximately 0.8 cm in short diameter located in the left carotid sheath area (Figure 1C-F).
Figure 1

X-ray and magnetic resonance images. A and B: No significant abnormality on antero-posterior (A) and lateral (B) X-rays of the left elbow joint; C and D: Sagittal (C) and coronal (D) magnetic resonance images (MRI) showing significant abnormal signal in the left brachial plexus; E and F: Coronal MRI showing significant abnormal signal in the left brachial plexus. The red arrow points to the lesion.

X-ray and magnetic resonance images. A and B: No significant abnormality on antero-posterior (A) and lateral (B) X-rays of the left elbow joint; C and D: Sagittal (C) and coronal (D) magnetic resonance images (MRI) showing significant abnormal signal in the left brachial plexus; E and F: Coronal MRI showing significant abnormal signal in the left brachial plexus. The red arrow points to the lesion.

FINAL DIAGNOSIS

MS causing ulnar nerve entrapment.

TREATMENT

The patient was placed in a supine position, and an upper arm tourniquet was applied. After routine prepping and draping, a longitudinal incision of approximately 20 cm was made on the medial side of the left upper arm. Intraoperatively, the left ulnar nerve was found to be thickened and degenerated, with severe adhesions to the surrounding tissues. Further observation of the ulnar nerve revealed thickening of the epineurium and hyperplasia of the perineurium, trapping the nerve fibres; therefore, interfascicular neurolysis release was performed with careful separation of the hyperplastic tissue between the nerve bundles. In addition, the lymph nodes in the anterior axillary region were cleared and sent for pathological examination. The incision was closed in layers after irrigation and haemostasis. Postoperative pathological findings were as follows: Lymphohaematopoietic tumour (both neuroepithelial and lymph nodes), combined with immunohistochemical staining results consistent with MS [CD3 (-), CD20 (-), CD21:FDC network (+), CD5 (-), Ki-67 (+ 70%), TdT (-), LCA (+), MPO (+), CD117 (+), and CD34 (+)] (Figures 2 and 3).
Figure 2

Intraoperative and histological images. A: Intraoperative thickening and degeneration of the left ulnar nerve; B: Hematoxylin and eosin-stained section showing neuroepithelial and lymph node pathology.

Figure 3

Histopathology of myeloid sarcoma. Immunopathological examination shows tissue of lymphohaematopoietic lineage. A: CD21; B: Ki-67; C: LCA; D: MPO; E: CD117; F: CD34.

Intraoperative and histological images. A: Intraoperative thickening and degeneration of the left ulnar nerve; B: Hematoxylin and eosin-stained section showing neuroepithelial and lymph node pathology. Histopathology of myeloid sarcoma. Immunopathological examination shows tissue of lymphohaematopoietic lineage. A: CD21; B: Ki-67; C: LCA; D: MPO; E: CD117; F: CD34.

OUTCOME AND FOLLOW-UP

On the first postoperative day, the patient’s pain and numbness were significantly reduced. After 1 wk of observation, we actively communicated with the patient and his family and transferred him to the external haemato-oncology department for further treatment of the primary disease. Positron emission tomography/computerised tomography (PET/CT) was performed, and the results were consistent with MS as per the pathology report. At the 2-mo follow-up, the patient had recovered well from the hand symptoms, the numbness had disappeared, and the postoperative visual analogue scale (VAS) score of pain had decreased to 1 from 5 preoperatively.

DISCUSSION

The incidence of MS in acute myeloid leukaemia (AML) patients ranges from 3%-5%[8]. Although the exact pathogenesis of MS is not fully understood, multivariate analysis has demonstrated that the occurrence of MS is significantly associated with intrinsic properties of myeloid tumour cells (e.g., cytogenetics)[9-11]. MS may manifest in many different parts of the body, including peripheral nerves, and its clinical symptoms depend on the specific location and size of the tumour, making it very difficult for doctors to diagnose based on symptoms alone[12-16]. For early MS diagnosis, biopsy and PET/CT images are useful, with the maximum standardized uptake value (SUVmax) on PET/CT images for MS detection often in the range of 2.1-9.3, while MRI can only be used to detect tissue abnormalities and not to provide a definitive diagnosis[7,17]. Ultrasound of areas affected by MS can also be valuable in the assessment of mass size and borders[18]. The aim of tissue biopsy is diagnostic clarification, with cytochemical and immunophenotypic analyses, such as myeloid cell markers, anti-myeloperoxidase, and lysozyme, being particularly helpful in gaining a definitive diagnosis[19-23]. Studies have shown that MS is often misdiagnosed as non-Hodgkin’s lymphoma, and in the absence of immunohistochemical results, the misdiagnosis rate is 50%-75%[24]. It has also been shown that 88% of patients with untreated isolated MS progress to AML within 1 year[25] and that MS is a precursor to relapse of the primary disease[8,26,27]. Due to its rarity, case reports mostly constitute the literature for MS, and studies on treatment options are mainly retrospective analyses of small sample sizes, with a lack of large randomized prospective studies[28-30]. Therefore, a uniform and consistent approach to optimal treatment has not been established. However, given the risk of progression to leukaemia and the poor prognosis, the main aim of treatment is to delay progression and prolong survival as long as possible[19,31-33]. We review cases of peripheral nerve compression due to MS over the last 10 years (Table 1) and found that similar cases were predominantly observed when MS invaded the eye (3 cases) and spine (12 cases), while invasion of the brachial plexus is very rare. Due to the rarity of MS-associated peripheral nerve compression, the resulting misdiagnosis may lead to a delay in optimal MS treatment[31,34].
Table 1

Cases of peripheral nerve compression due to myeloid sarcoma over the last 10 years

Ref.
Gender/age (yr)
Leukaemia-Yes (type)/No
Symptoms
Involved segment
Lesion invasion site
Imaging
Bone marrow biopsy
Laboratory test findings
Treatment regimens
Pathology and immunohistochemistry examination
McCarty et al[35]M/14NoHeadaches, urinary incontinenceIntracranial, extracranial, sacral spineCerebral nerve, sacral nerve rootMRIPositiveWBC: 51 × 109/L; HGB: 113 g/L; platelets: 130 × 109/LRadiotherapy, chemotherapy-
Zhu et al[36]M/36NoAbdominal pain, pain in right eye, eye protrusion with inability to closePancreas, right eyePancreas, right optic nerveCT, MRI, PET-CTNegativeMildly elevated liver and pancreatic enzymesRadiotherapy, chemotherapyKi-67 (+ 80%), P53 (approximately 50%), CD43 (+), MPO (+)
Bai et al[24]M/29NoSevere radiating pain in lower limbs, moderate difficulty in urinationWaistLumbar spine attachment, spinal cordCT, MRI, SPECTNegativeWBC: 6.01 × 109/L; RBC: 5.00 × 1012/L; HGB: 158 g/L; platelets: 236 × 109/L; CRP: 2 mg/L; rrythrocyte sedimentation rate (ESR): 4 mm/1 h; procalcitonin (PCT): 0.27 ng/mLLesion excision, chemotherapyCD33 (+), MPO (+)
Valsamis et al[37]M/56NoPain in right hip radiating down right legRight hipRight sciatic nerve, lumbosacral plexusUltrasound, MRI-MONO: 0.9 × 109/L; RBC: 3.56 × 1012/L; HGB: 116 g/L; mean cell volume: 102 fL; CRP: 13 mg/L--
Pandey et al[38](1) F/44; (2) F/16; (3) F/63; (4) M/53(1,2,4) No; (3) Yes (AML)(1) Neck pain, right arm weakness, and muscle wasting; (2) back pain, bilateral lower extremity tingling, and weakness; (3) lower back pain, bilateral lower extremity weakness, and bowel incontinence; and (4) lower back pain, hip pain, lower extremity weakness, and muscle pain(1) Cervical spine; (2) thoracic spine; (3) thoracic spine; and (4) lumbar spineSpinal cord compression-(1) Negative; (2) positive; (3) negative; and (4) positive(1) and (3) Negative; (2) and (4) high WBCLesion excision-
Snoj et al[39]F/49Yes [MDS (refractory anaemia with excess blasts)]Weakness and decreased sensation in right arm, right supraclavicular massLeft upper limbLeft brachial plexusUltrasound, MRI--Radiotherapy, chemotherapy-
Yamamoto et al[40]F/34Yes (Chronic phase chronic myeloid leukaemia)Pain in left eye, protrusion of eyeball, blurred vision with headache, and vomitingLeft eyeLeft optic nerveMRI---CD13 (+), CD33 (+), CD117 (+)
Koh et al[41]M/68Yes (chronic myeloid leukemia)Low back pain and numbness in both legs with radiating painThoracic and sacral spineSpinal cordMRI, CT--Chemotherapy-
Kim et al[42]M/62Yes (acute myeloid leukaemia, M2)Abnormal sensation and weakness of ankle flexion in posterior aspect of left calf and footLower left limbSciatic nerveUltrasound, MRI---MPO (+)
Rambeloson et al[43]M/1NoBilateral ophthalmoplegia with loss of visionBilateral eyeOcculomotor nerveMyelogram, CT----
Slouma et al[31]M/56NoProgressive back pain and bilateral sciaticaWaistLumbar 5th nerve rootMRI-WBC: 83 × 109/L; absolute neutrophil count: 60 × 109/LChemotherapyMPO (+), CD13 (+), CD33 (+), CD14 (+), CD4 (+), CD46 (+)
Anqi et al[44]M/24NoLimp, numbness in right lower limb, mild urinary frequency, urinary and faecal incontinenceLumbosacral regionLumbar and sacral spineMRI-NormalLesion excision, chemotherapyMPO, CD34, CD43 (+)
Ha et al[34]F/38Yes (AML)Subacute radiating pain in right upper limb, weaknessRight upper limbRight brachial plexusMRI, PET/CT--Chemotherapy, hormone shock therapyCD13(+), CD14 (+) ,CD15 (+), CD33 (+), CD54 (+), CD64 (+), CD117 (+) , MPO (+)

SPECT: Single-photon emission computed tomography; WBC: White blood cell count; RBC: Red blood cell count; MRI: Magnetic resonance imaging; MS: Myeloid sarcoma; PET/CT: Positron emission tomography/computerised tomography; CRP: C-reactive protein; AML: Acute myeloid leukaemia; HGB: Haemoglobin count; ESR: Erythrocyte sedimentation rate; PCT: Procalcitonin.

Cases of peripheral nerve compression due to myeloid sarcoma over the last 10 years SPECT: Single-photon emission computed tomography; WBC: White blood cell count; RBC: Red blood cell count; MRI: Magnetic resonance imaging; MS: Myeloid sarcoma; PET/CT: Positron emission tomography/computerised tomography; CRP: C-reactive protein; AML: Acute myeloid leukaemia; HGB: Haemoglobin count; ESR: Erythrocyte sedimentation rate; PCT: Procalcitonin. The clearest symptom in the present case was ulnar nerve palsy, most typically caused by cubital tunnel syndrome. As our investigations showed that the nerve signal was abnormal, we first explored and released the nerve. This resulted in a significant reduction in the patient’s pain, and numbness was significantly reduced on the first postoperative day. The subsequent pathology results were unexpected, but we were able to expedite referral to haemato-oncology for primary disease treatment.

CONCLUSION

MS causing ulnar nerve entrapment and degeneration through invasion of the brachial plexus is a very rare condition. With a history of ANLL with nerve entrapment features, it is essential to suspect MS and send tissue for pathological analysis, as well as to provide prompt surgical decompression for symptom relief and prevent lasting neurological damage.
  44 in total

1.  Allogeneic Hematopoietic Stem Cell Transplantation as Treatment for Primary Granulocytic Sarcoma of the Breast.

Authors:  Xiaolin Li; Jie Fu; Yan Xue; Yang Yang; Yang Wang; Cixian Zhang; Shichao Zhuo; Farzan Irani
Journal:  Cell Biochem Biophys       Date:  2015-07       Impact factor: 2.194

2.  An isolated myeloid blast crisis presenting as optic nerve sarcoma in a patient with chronic myeloid leukaemia treated with imatinib.

Authors:  Hisashi Yamamoto; Masakazu Yamamoto; Eijiro Omoto; Takeo Kato; Katsushi Tajima
Journal:  Br J Haematol       Date:  2015-06-01       Impact factor: 6.998

Review 3.  Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.

Authors:  L Max Almond; Maria Charalampakis; Samuel J Ford; David Gourevitch; Anant Desai
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

4.  [Myeloid sarcoma].

Authors:  Hans Jonas Meyer; Alexey Surov
Journal:  Rofo       Date:  2020-04-30

5.  Granulocytic sarcoma: 32 cases and review of the literature.

Authors:  Semra Paydas; Suzan Zorludemir; Melek Ergin
Journal:  Leuk Lymphoma       Date:  2006-12

6.  18F-FDG PET/CT Helps Differentiate Peripheral Nerve Myeloid Sarcoma From a Presumed Benign Nerve Sheath Tumor.

Authors:  Jeeban P Das; Christopher C Riedl; Gary A Ulaner
Journal:  Clin Nucl Med       Date:  2020-12       Impact factor: 7.794

7.  Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: a single-center analysis.

Authors:  Ji-Min Shi; Xiao-Jian Meng; Yi Luo; Ya-Min Tan; Xiao-Li Zhu; Gao-Feng Zheng; Jing-Song He; Wei-Yan Zheng; Wan-Zhuo Xie; Li Li; Xiu-Jin Ye; Jie Zhang; Zhen Cai; Mao-Fang Lin; He Huang
Journal:  Leuk Res       Date:  2013-01-21       Impact factor: 3.156

Review 8.  Sacral canal myeloid sarcoma as initial manifestation of granulocytic leukemia: MRI features and differential diagnosis (with a case report).

Authors:  Xiao Anqi; Huang Siqing; Li Zhenlin; You Chao
Journal:  Turk Neurosurg       Date:  2014       Impact factor: 1.003

9.  Acute Promyelocytic Leukemia Presenting With a Myeloid Sarcoma of the Spine: A Case Report and Literature Review.

Authors:  Xuemei Shu; Qiuling Wu; Tao Guo; Hua Yin; Jingdi Liu
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.